5h agoInvesting.com MarketsNEUTRAL 50General
Why is Alvotech stock surging today?
Why is Alvotech stock surging today?
Archived explainer. For the current picture see today's ALVO page.
Why Is ALVOTECH (ALVO) Stock Up Today?
By the Top Tier Newswire AI Desk · October 5, 2026 at 9:33 AM ET · reviewed against 4 wire stories
ALVOTECH (ALVO) is up +13.30% in the latest session. Our newswire has captured 4 stories on ALVO across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ALVO stock is up today
Alvotech stock surged 13.30% to $6.18 on October 5, 2026, driven by the U.S. Food and Drug Administration’s approval of a supplement to the Biologics License Application for AVT02, the company’s biosimilar to Humira marketed as SIMLANDI®. The approval allows for commercial drug substance to be manufactured in a second production suite at Alvotech’s Reykjavik facility, effectively doubling its U.S. drug-substance capacity. The move follows the resolution of FDA inspection-related matters at the site and is expected to enhance the company’s production flexibility and supply chain reliability.
What Happened
Alvotech announced that the FDA approved the supplement to the BLA for AVT02, enabling the U.S. commercial supply of SIMLANDI® to be produced in either of the company’s two Reykjavik manufacturing suites. This approval is a significant step in the company’s strategy to scale its biosimilar offerings in the U.S. market. The company also noted that the approval further confirms the resolution of prior inspection issues at the facility, which had previously raised concerns about its regulatory compliance and operational capacity.
What The Data Shows
The stock opened at $5.93, reflecting an 8.8% gap from the previous close of $5.45. It reached a session high of $6.20 at 9:30 AM ET and closed the session at $6.11. Trading volume was 0.3 million shares, which is 0.3 times the 3-month daily average. The stock has been volatile recently, having fallen 5.9% over the past 8 sessions, from $5.81 to $5.47. On October 5, it printed a fresh 52-week high, indicating renewed investor confidence despite the company’s ongoing unprofitability and negative revenue growth.
What To Watch
Alvotech has no scheduled earnings report in the immediate future. Investors should monitor the breadth of coverage and analyst sentiment in the coming days, particularly as the market digests the implications of the expanded manufacturing capacity and its potential impact on future revenue and operational efficiency.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ALVO by the numbers
Last: $6.18Session: +13.30%7 sessions: +3.88%Coverage: 4 stories / 4 sourcesAI sentiment: 64/100 (bullish)Mkt cap: $1.9B52w: $2.94 to $9.04
The headlines behind the move
7h agoMarketChameleonBULLISH 73Product/PR
FDA greenlights SIMLANDI manufacturing in a second Reykjavik suite, effectively doubling ALVO’s U.S. drug-substance capacity October 5, 2026
Alvotech said the FDA approved a supplement to the BLA for AVT02 (SIMLANDI®), allowing U.S. commercial drug substance to be manufactured in a second production suite at its Reykjavik facility. The company said adding DSM2 “effectively doubles” U.S.-supporting capacity and further confirms resolution of FDA inspection-related matters at the site, potentially supporting action on other pending BLAs tied to the facility.
9h agoThe FlyBULLISH 67Product/PR
Alvotech gets FDA approval of more U.S. manufacturing capacity for Simlandi
10h agoBusiness InsiderBULLISH 67Product/PR
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the Reykjavik...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ALVO: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ALVO move explainers: 2026-10-05 · 2026-09-16 · 2026-08-31